NASDAQ:LHDX

Lucira Health Competitors

$4.56
-0.37 (-7.51 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.49
$5.02
50-Day Range
$4.93
$15.05
52-Week Range
$4.49
$37.99
Volume264,421 shs
Average Volume635,395 shs
Market Capitalization$175.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Lucira Health (NASDAQ:LHDX) Vs. OSUR, CALT, CMRX, SPNE, ATHA, and DBVT

Should you be buying LHDX stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Lucira Health, including OraSure Technologies (OSUR), Calliditas Therapeutics AB (publ) (CALT), Chimerix (CMRX), SeaSpine (SPNE), Athira Pharma (ATHA), and DBV Technologies (DBVT).

Lucira Health (NASDAQ:LHDX) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Lucira Health and OraSure Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lucira Health11102.00
OraSure Technologies01402.80

Lucira Health currently has a consensus target price of $9.00, indicating a potential upside of 97.37%. OraSure Technologies has a consensus target price of $17.60, indicating a potential upside of 80.88%. Given Lucira Health's higher probable upside, research analysts clearly believe Lucira Health is more favorable than OraSure Technologies.

Valuation and Earnings

This table compares Lucira Health and OraSure Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucira HealthN/AN/AN/AN/AN/A
OraSure Technologies$154.60 million4.53$16.66 million$0.1374.85

OraSure Technologies has higher revenue and earnings than Lucira Health.

Profitability

This table compares Lucira Health and OraSure Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lucira HealthN/AN/AN/A
OraSure Technologies-9.05%-3.51%-3.13%

Institutional and Insider Ownership

98.1% of OraSure Technologies shares are held by institutional investors. 1.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

OraSure Technologies beats Lucira Health on 5 of the 9 factors compared between the two stocks.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Lucira Health (NASDAQ:LHDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Analyst Recommendations

This is a summary of recent ratings and price targets for Calliditas Therapeutics AB (publ) and Lucira Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Calliditas Therapeutics AB (publ)00503.00
Lucira Health11102.00

Calliditas Therapeutics AB (publ) presently has a consensus price target of $40.80, indicating a potential upside of 47.40%. Lucira Health has a consensus price target of $9.00, indicating a potential upside of 97.37%. Given Lucira Health's higher probable upside, analysts plainly believe Lucira Health is more favorable than Calliditas Therapeutics AB (publ).

Earnings & Valuation

This table compares Calliditas Therapeutics AB (publ) and Lucira Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$19.56 million35.34$-3,450,000.00($0.19)-145.68
Lucira HealthN/AN/AN/AN/AN/A

Lucira Health has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

Profitability

This table compares Calliditas Therapeutics AB (publ) and Lucira Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%
Lucira HealthN/AN/AN/A

Institutional & Insider Ownership

11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Calliditas Therapeutics AB (publ) beats Lucira Health on 4 of the 7 factors compared between the two stocks.

Chimerix (NASDAQ:CMRX) and Lucira Health (NASDAQ:LHDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Chimerix and Lucira Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chimerix-321.31%-36.57%-33.53%
Lucira HealthN/AN/AN/A

Institutional & Insider Ownership

45.4% of Chimerix shares are owned by institutional investors. 9.0% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Chimerix and Lucira Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chimerix$12.52 million55.16$-112,580,000.00($0.86)-9.31
Lucira HealthN/AN/AN/AN/AN/A

Lucira Health has lower revenue, but higher earnings than Chimerix.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Chimerix and Lucira Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chimerix00503.00
Lucira Health11102.00

Chimerix currently has a consensus target price of $18.80, indicating a potential upside of 134.71%. Lucira Health has a consensus target price of $9.00, indicating a potential upside of 97.37%. Given Chimerix's stronger consensus rating and higher possible upside, analysts plainly believe Chimerix is more favorable than Lucira Health.

Summary

Chimerix beats Lucira Health on 6 of the 9 factors compared between the two stocks.

Lucira Health (NASDAQ:LHDX) and SeaSpine (NASDAQ:SPNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Earnings & Valuation

This table compares Lucira Health and SeaSpine's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucira HealthN/AN/AN/AN/AN/A
SeaSpine$159.08 million4.34$-39,280,000.00($2.07)-10.05

Lucira Health has higher earnings, but lower revenue than SeaSpine.

Analyst Ratings

This is a breakdown of recent ratings for Lucira Health and SeaSpine, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lucira Health11102.00
SeaSpine00603.00

Lucira Health currently has a consensus target price of $9.00, indicating a potential upside of 97.37%. SeaSpine has a consensus target price of $24.00, indicating a potential upside of 15.33%. Given Lucira Health's higher possible upside, research analysts clearly believe Lucira Health is more favorable than SeaSpine.

Profitability

This table compares Lucira Health and SeaSpine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lucira HealthN/AN/AN/A
SeaSpine-27.32%-24.38%-19.64%

Institutional and Insider Ownership

76.7% of SeaSpine shares are owned by institutional investors. 9.8% of SeaSpine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

SeaSpine beats Lucira Health on 5 of the 9 factors compared between the two stocks.

Lucira Health (NASDAQ:LHDX) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Lucira Health and Athira Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucira HealthN/AN/AN/AN/AN/A
Athira PharmaN/AN/A$-5,160,000.00N/AN/A

Insider and Institutional Ownership

66.7% of Athira Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Lucira Health and Athira Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lucira HealthN/AN/AN/A
Athira PharmaN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Lucira Health and Athira Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lucira Health11102.00
Athira Pharma00403.00

Lucira Health presently has a consensus price target of $9.00, suggesting a potential upside of 97.37%. Athira Pharma has a consensus price target of $42.50, suggesting a potential upside of 128.86%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than Lucira Health.

Summary

Athira Pharma beats Lucira Health on 4 of the 4 factors compared between the two stocks.

Lucira Health (NASDAQ:LHDX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Profitability

This table compares Lucira Health and DBV Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lucira HealthN/AN/AN/A
DBV TechnologiesN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Lucira Health and DBV Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lucira Health11102.00
DBV Technologies04502.56

Lucira Health presently has a consensus price target of $9.00, suggesting a potential upside of 97.37%. DBV Technologies has a consensus price target of $7.25, suggesting a potential upside of 16.56%. Given Lucira Health's higher probable upside, analysts clearly believe Lucira Health is more favorable than DBV Technologies.

Insider & Institutional Ownership

32.5% of DBV Technologies shares are held by institutional investors. 15.3% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Lucira Health and DBV Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucira HealthN/AN/AN/AN/AN/A
DBV Technologies$14.75 million46.33$-172,020,000.00($2.33)-2.67

Lucira Health has higher earnings, but lower revenue than DBV Technologies.

Summary

DBV Technologies beats Lucira Health on 5 of the 6 factors compared between the two stocks.


Lucira Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.73-1.3%$700.04 million$154.60 million-42.30Earnings Announcement
Analyst Revision
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.68-1.3%$691.20 million$19.56 million-19.91Upcoming Earnings
Chimerix logo
CMRX
Chimerix
1.7$8.01-1.7%$690.55 million$12.52 million-14.05Earnings Announcement
SeaSpine logo
SPNE
SeaSpine
1.5$20.81-2.4%$690.08 million$159.08 million-12.46Analyst Report
Athira Pharma logo
ATHA
Athira Pharma
1.7$18.57-0.5%$689.32 millionN/A0.00
DBV Technologies logo
DBVT
DBV Technologies
1.1$6.22-4.0%$683.41 million$14.75 million-2.67Gap Down
AKYA
Akoya BioSciences
0.0$19.13-3.2%$682.73 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.3$15.00-8.7%$681.83 million$22.99 million-7.98Earnings Announcement
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.64-5.3%$671.08 million$2.22 million-15.53Upcoming Earnings
Agenus logo
AGEN
Agenus
1.6$3.01-2.0%$669.55 million$150.05 million-2.76Earnings Announcement
Analyst Revision
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$15.43-5.4%$653.97 million$17.26 million-4.29
Ardelyx logo
ARDX
Ardelyx
1.6$6.55-2.9%$646.41 million$5.28 million-6.49Earnings Announcement
Analyst Revision
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.80-0.8%$641.43 million$123.86 million63.34Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.98-7.4%$641.31 million$150,000.00-4.26Earnings Announcement
Analyst Report
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.8$19.42-1.2%$639.04 millionN/A-10.33News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$23.13-4.8%$638.92 million$23.60 million-16.52Earnings Announcement
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$5.14-6.2%$635.79 million$2.51 million-3.12
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.39-4.3%$633.71 million$322.07 million-4.18Earnings Announcement
Global Cord Blood logo
CO
Global Cord Blood
0.8$5.21-1.0%$633.28 million$172.50 million8.83
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$22.15-0.6%$624.45 million$148.36 million-5.75Earnings Announcement
Gap Up
Kadmon logo
KDMN
Kadmon
1.8$3.61-5.0%$620.26 million$5.09 million-6.02Earnings Announcement
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$12.38-1.5%$619.52 million$19.89 million-5.84News Coverage
Gap Up
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$8.19-2.6%$615.01 million$40.89 million-2.82Analyst Report
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.23-4.5%$610.13 million$1.19 million-6.76Earnings Announcement
Analyst Report
News Coverage
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.00-3.9%$607.28 millionN/A-2.25Earnings Announcement
Analyst Report
Intersect ENT logo
XENT
Intersect ENT
1.7$18.22-15.5%$603.74 million$109.14 million-9.54Earnings Announcement
News Coverage
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.68-2.8%$602.34 millionN/A-5.30Earnings Announcement
Analyst Upgrade
Analyst Revision
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.6$24.65-2.3%$599.19 million$12.69 million-11.85
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.50-3.3%$597.81 million$13.29 million-9.57
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.50-1.2%$596.23 million$114.51 million-88.30Earnings Announcement
Triple-S Management logo
GTS
Triple-S Management
1.1$24.81-0.1%$587.53 million$3.38 billion10.69Earnings Announcement
FNCH
Finch Therapeutics Group
2.0$12.40-2.1%$584.60 millionN/A0.00
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.57-5.1%$578.94 millionN/A-16.00Upcoming Earnings
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.91-4.6%$578.86 millionN/A-6.11Earnings Announcement
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$27.91-7.4%$577.85 millionN/A0.00
SOC Telemed logo
TLMD
SOC Telemed
1.6$7.50-4.1%$575.80 millionN/A0.00Upcoming Earnings
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04-3.7%$572.43 millionN/A-9.33Earnings Announcement
Analyst Revision
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$16.95-1.2%$562.10 million$252 million-1.73Earnings Announcement
Analyst Report
Analyst Revision
Inhibrx logo
INBX
Inhibrx
1.6$14.81-6.6%$559.97 millionN/A0.00
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$28.90-3.5%$554.71 million$9.64 million-4.71Earnings Announcement
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.29-6.6%$553.15 million$143.01 million-1.01Earnings Announcement
Analyst Revision
Inventiva logo
IVA
Inventiva
1.4$14.16-1.7%$547.00 millionN/A0.00
Inventiva logo
IVA
Inventiva
0.0$14.16-1.7%$547.00 millionN/A0.00
ACHL
Achilles Therapeutics plc American Depositary Shares
1.6$13.40-5.7%$544.34 millionN/A0.00Quiet Period Expiration
Gap Down
Aspira Women's Health logo
AWH
Aspira Women's Health
1.4$4.85-7.2%$542.94 million$4.54 million-32.33Upcoming Earnings
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.72-5.4%$539.43 millionN/A-5.15Earnings Announcement
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.17-6.6%$539.42 million$59.29 million-21.13Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Ontrak logo
OTRK
Ontrak
1.7$30.21-5.2%$535.84 million$35.10 million-17.77Analyst Report
Veru logo
VERU
Veru
1.4$7.39-5.7%$531.43 million$42.59 million-26.39Upcoming Earnings
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$6.95-5.5%$528.65 million$26.74 million17.38
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.